315 related articles for article (PubMed ID: 22469984)
1. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Shi J; Wang E; Zuber J; Rappaport A; Taylor M; Johns C; Lowe SW; Vakoc CR
Oncogene; 2013 Feb; 32(7):930-8. PubMed ID: 22469984
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
3. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
4. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
5. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a.
Shields BJ; Jackson JT; Metcalf D; Shi W; Huang Q; Garnham AL; Glaser SP; Beck D; Pimanda JE; Bogue CW; Smyth GK; Alexander WS; McCormack MP
Genes Dev; 2016 Jan; 30(1):78-91. PubMed ID: 26728554
[TBL] [Abstract][Full Text] [Related]
7. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
[TBL] [Abstract][Full Text] [Related]
8. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.
Tan J; Jones M; Koseki H; Nakayama M; Muntean AG; Maillard I; Hess JL
Cancer Cell; 2011 Nov; 20(5):563-75. PubMed ID: 22094252
[TBL] [Abstract][Full Text] [Related]
9. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
[TBL] [Abstract][Full Text] [Related]
11. CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.
Cordonnier G; Mandoli A; Cagnard N; Hypolite G; Lhermitte L; Verhoeyen E; Asnafi V; Dillon N; Macintyre E; Martens JHA; Bond J
Cell Rep; 2020 Jan; 30(2):299-307.e3. PubMed ID: 31940477
[TBL] [Abstract][Full Text] [Related]
12. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
Kim WI; Matise I; Diers MD; Largaespada DA
Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.
Lee SC; Miller S; Hyland C; Kauppi M; Lebois M; Di Rago L; Metcalf D; Kinkel SA; Josefsson EC; Blewitt ME; Majewski IJ; Alexander WS
Blood; 2015 Jul; 126(2):167-75. PubMed ID: 26036803
[TBL] [Abstract][Full Text] [Related]
14. Polycomb complexes in MLL-AF9-related leukemias.
Sparavier A; Di Croce L
Curr Opin Genet Dev; 2022 Aug; 75():101920. PubMed ID: 35609423
[TBL] [Abstract][Full Text] [Related]
15. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
[TBL] [Abstract][Full Text] [Related]
16. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
17. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
18. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
[TBL] [Abstract][Full Text] [Related]
20. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
Ren Z; Kim A; Huang YT; Pi WC; Gong W; Yu X; Qi J; Jin J; Cai L; Roeder RG; Chen WY; Wang GG
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
